Table 2.
(A) Univariate analysis of the relationship of clinical and urinary markers with annualized slope of eGFR over 4-year follow up. (B) Multivariate analysis of the relationship of clinical and urinary markers with annualized slope of eGFR over 4-year follow up.
| Variable | Coefficient | SE | P value | 95% CI (LCL, UCL) |
|---|---|---|---|---|
| (A) | ||||
| Age (years) | − 0.03 | 0.31 | 0.36 | − 0.90, 0.03 |
| Males | − 0.51 | 0.62 | 0.42 | − 1.75, 0.73 |
| eGFR (ml/min/1.73m2) | − 0.007 | 0.17 | 0.66 | − 0.04, 0.03 |
| BMI (kg/m2) | 0.04 | 0.08 | 0.65 | − 0.12, 0.19 |
| MAP (mm Hg) | − 0.01 | 0.02 | 0.66 | − 0.06, 0.04 |
| HbA1c (%) | − 0.39 | 0.41 | 0.35 | − 1.20, 0.43 |
| UAlb:CR (mg/gCre) | − 0.002 | 0.0004 | < 0.001 | − 0.002, − 0.0007 |
| UPPod:CR (M/gCre) | − 0.02 | 0.005 | < 0.001 | − 0.03, − 0.01 |
| UPAqp2:CR (M/gCre) | − 0.0009 | 0.0005 | 0.10 | − 0.002, 0.0001 |
| UPPod:Neph | − 0.02 | 0.01 | 0.16 | − 0.04, 0.007 |
| UPPod:Aqp2 | − 0.31 | 0.20 | 0.12 | − 0.70, 0.09 |
| ACEi/ARB use | − 0.81 | 0.60 | 0.18 | − 1.99, 0.37 |
| Insulin use | − 0.46 | 0.62 | 0.46 | − 1.68, 0.77 |
| Biguanides use | 0.06 | 0.65 | 0.93 | − 1.24, 1.35 |
| DPP4i use | − 0.83 | 0.61 | 0.18 | − 2.04, 0.38 |
| GLP1R use | 0.23 | 1.14 | 0.84 | − 2.03, 2.49 |
| (B) | ||||
| Age (years) | − 0.06 | 0.03 | 0.09 | − 0.125, 0.009 |
| Males | − 0.94 | 0.59 | 0.11 | − 2.110, 0.226 |
| eGFR (ml/min/1.73m2) | − 0.03 | 0.02 | 0.09 | − 0.071, 0.005 |
| HbA1c (%) | − 0.39 | 0.39 | 0.31 | − 1.150, 0.378 |
| MAP (mm Hg) | − 0.008 | 0.02 | 0.72 | − 0.053, 0.040 |
| ACEi/ARB use | − 0.17 | 0.58 | 0.77 | − 1.330, − 0.980 |
| UPPod:CR (M/gCre) | − 0.01 | 0.005 | 0.01 | − 0.024, − 0.003 |
| UAlb:CR (mg/gCre) | − 0.002 | 0.0005 | 0.004 | − 0.003, − 0.0005 |